Dr. Lynn M. Taussig Named Chairman of iSonea’s Medical Advisory Board

SEVERNA PARK, Md.--()--Medical technology company iSonea Ltd. (ASX: ISN; OTCQX: ISOAY) today announced that Lynn M. Taussig, M.D., Special Advisor to the Provost for the Life Sciences at the University of Denver and the retired president and CEO of National Jewish Medical and Research Center, has been named Chairman of iSonea’s Medical Advisory Board (MAB).

The mission of the MAB is to advise iSonea on clinical studies related to the commercial development of its Acoustic Respiratory Monitoring™ (ARM) devices and mobile health applications for the management of asthma and related respiratory disorders. In particular, Dr. Taussig will provide input, guidance and feedback to the iSonea senior management team on the latest clinical research in the field, study protocol, and current and future product development.

Dr. Taussig is a renowned authority on asthma and is the author of more than 180 scientific publications and six books and monographs. For eleven years, he was the Chair of the Steering Committee of the National Institute of Health's Childhood Asthma Research and Education Network. He currently chairs another steering committee and two Data Safety Monitoring Boards for the National Institute of Health’s National Heart, Lung and Blood Institute (NHLBI). Prior to assuming his positions at National Jewish Medical and Research Center, he was Professor and Chair, Department of Pediatrics and Director, Steele Children's Research Center at the University of Arizona Health Sciences Center. He is the recipient of 44 honors and awards from schools, universities and communities around the world.

“I am honored to serve as Chairman of iSonea’s Medical Advisory Board,” said Dr. Taussig. “iSonea’s devices and mobile applications will address a significant unmet medical need for easy-to-use asthma monitoring devices. The innovative technology that iSonea is designing has the potential to help patients and caregivers, in collaboration with their physicians, do a better job of managing costly, chronic respiratory disorders. The ultimate goals of better monitoring are to improve outcomes while minimizing risks.”

"We appreciate Dr. Taussig’s insights and guidance as we work to strengthen the evidence basis for Acoustic Respiratory Monitoring in clinical practice and in real-life settings,” said Jonathan Freudman, M.D., medical director for iSonea Ltd. "The Medical Advisory Board’s input has already been instrumental in helping us design the pediatric wheeze rate monitoring study that we will be initiating this spring.”

About iSonea Limited

iSonea Limited (ASX:ISN; OTCQX:ISOAY) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea’s proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense™ mobile applications, iSonea is turning smartphones into medical devices--enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea’s ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE. For more information, please visit www.iSoneaMed.com.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on iSonea’s current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks,” "estimates,“ “guidance” and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Contacts

iSonea Limited
Michael Thomas, +1-410-777-5251
Chief Executive Officer
mthomas@iSoneaMed.com
www.iSoneaMed.com
or
Schwartz MSL Boston
Helen Shik or Jane Hauser, +1-781-684-0770
iSonea@schwartzmsl.com
www.schwartzmsl.com

Release Summary

iSonea Ltd. announces Lynn M. Taussig, M.D., Special Advisor to the Provost for the Life Sciences at the Univ. of Denver has been named Chairman of iSonea’s Medical Advisory Board.

Contacts

iSonea Limited
Michael Thomas, +1-410-777-5251
Chief Executive Officer
mthomas@iSoneaMed.com
www.iSoneaMed.com
or
Schwartz MSL Boston
Helen Shik or Jane Hauser, +1-781-684-0770
iSonea@schwartzmsl.com
www.schwartzmsl.com